

PUBLICATIONS

Peer Reviewed Articles

1. LEYVRAZ S, **KETTERER N**, VUICHARD P, VON FLIEDNER V, LEJEUNE F, SCHNEIDER P, GROB JP, BACHMANN F : Sequential high dose combination chemotherapy with granulocyte colony-stimulating factor and peripheral blood progenitor cells in patients with solid tumors : intensification limited by nonhaematologic effects. **J Natl Cancer Inst** 1993;85:1962-64
2. LEYVRAZ S, **KETTERER N**, PEREY L, BAUER J, VUICHARD P, GROB JP, SCHNEIDER P, VON FLIEDNER V, LEJEUNE F, BACHMANN F :Intensification of chemotherapy for the treatment of small cell lung cancer: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony stimulating factor. **Br J Cancer** 1995;72:178-182
3. **KETTERER N**, SALLES G, ESPINOUSE D, DUMONTET C, NEIDHARDT-BERARD EM, MOULLET I, BOUAFIA F, BERGER F, FELMAN P, COIFFIER B: Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. **Ann Oncol** 1997; 8: 701-704
4. **KETTERER N**, SALLES G, RABA M, ESPINOUSE D, SONET A, TREMISI P, DUMONTET C, MOULLET I, NEIDHARDT-BERARD EM, BOUAFIA F, COIFFIER B: High CD34+ cell counts decrease hematological toxicity of autologous peripheral blood progenitor cell transplantation. **Blood** 1998; 91: 3148-3155
5. DUMONTET C, **KETTERER N**, ESPINOUSE D, NEIDHARDT-BERARD EM, MOULLET I, THIEBLEMONT C, SALLES G, COIFFIER B: Reduced benefit of intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma in elderly patients. **Bone Marrow Transplant** 1998; 21: 1037-1041
6. SAMAHA H, DUMONTET C, **KETTERER N**, MOULLET I, THIEBLEMONT C, BOUAFIA F, CALLET-BAUCHU E, BERGER F, SALLES G, COIFFIER B: Mantle cell lymphoma: a retrospective study of 121 cases. **Leukemia** 1998, 12: 1281-1287
7. COIFFIER B, HAIOUN C, **KETTERER N**, ENGERT A, TILLY H, MA D, JOHNSON P, LISTER A, FEURING-BUSKE M, RADFORD JA, CAPDEVILLE R, DIEHL V, REYES F: Rituximab (anti-CD20 antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. **Blood** 1998; 92: 1927-1932
8. **KETTERER N**, SALLES G, MOULLET I, DUMONTET C, TREMISI P, RIGAL D, THIEBLEMONT C, NEIDHARDT-BERARD EM, SAMAHA H, COIFFIER B: Factors associated with successful mobilization of peripheral blood progenitor cells in patients with hematological malignancies: experience of a single institution. **Br J Haematol** 1998; 103: 235-242

9. MOULLET I, SALLES G, **KETTERER N**, DUMONTET C, BOUAFIA F, NEIDHARDT-BERARD EM, THIEBLEMONT C, FELMAN P, COIFFIER B: Frequency and significance of anemia in non-hodgkin's lymphoma patients. **Ann Oncol** 1998; 9: 1109-1115
10. **KETTERER N**, ESPINOUSE D, CHAUMARAT M, DUMONTET C, MOULLET I, RIEUX C, NEIDHARDT-BERARD EM, BOUAFIA F, COIFFIER B, SALLES G: Pattern of infections following peripheral blood progenitor cell transplantations for lymphoproliferative malignancies. **Am J Med** 1999; 106: 191-197
11. **KETTERER N**, SONET A, DUMONTET C, MOULLET I, NEIDHARDT-BERARD EM, ESPINOUSE D, BOUAFIA F, COIFFIER B, SALLES G: Toxicity of peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: analysis of 300 intensifications performed in a single institution. **Bone Marrow Transplant** 1999; 23: 1309-15
12. DEARDEN CE, MATUTES E, CAZIN B, TJONNFJORD GE, PARREIRA A, NOMDEDEU B, LEONI P, CLARK FJ, RADIA D, RASSAM SM, ROQUES T, **KETTERER N**, BRITO-BABAPULLE V, DYER MJ, CATOVSKY D: High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. **Blood** 2001; 98:1721-1726
13. STUPP R, BODMER A, DUVOISIN B, BAUER J, PEREY L, BAKR M, **KETTERER N**, LEYVRAZ S. Is cisplatin required for the treatment of non-small-cell lung cancer? experience and preliminary results of a phase i/ii trial with topotecan and vinorelbine. **Oncology** 2001; 61 (Suppl 1): 35-41
14. ZOUHAIR A, WEBER D, BELKACEMI Y, **KETTERER N**, DIETRICH PY, VILLA S, SCANDOLARO L, BIERI S, STUDER G, DELACRETAZ F, GIRARDET C, MIRIMANOFF RO, OZSAHIN M. Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. **Int J Radiat Oncol Biol Phys** 2002;52:652-6
15. D'ADDARIO G, DIETERLE A, TORHORST J, MAIBACH R, STAHEL R, EGLI F, LOHRI A, CAVALLI F, FEY M, **KETTERER N**, CERNY T. HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. **Leukemia & Lymphoma** 2003;44(1):133-8
16. HEQUET O, SALLES G, **KETTERER N**, ESPINOUSE D, DUMONTET C, THIEBLEMONT C, ARNAUD P, BOUAFIA F, COIFFIER B. Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. **Bone Marrow Transplant** 2003;32:89-95
17. SIEGENTHALER MA, VU DH, EBNOTHER M, **KETTERER N**, LUTHI F, SCHMID P, BARGETZI M, GASPARINI D, TISSOT JD. 'Agglutination and flocculation' of stem cells collected by apheresis due to cryofibrinogen. **Bone Marrow Transplant**. 2004;33:765-7
18. DELALOYE J, MERLANI G, PETIGNAT C, WENGER A, ZAMAN K, MONNERAT C, MATZINGER O, NENADOV BECK M, VUICHARD P, **KETTERER N**, TARR PE. Nosocomial Nontyphoidal Salmonellosis after Antineoplastic Chemotherapy: Reactivation of asymptomatic colonization? **Eur J Clin Microb Infect Dis**. 2004;23:751-8

19. GHIELMINI M, SCHMITZ SF, COGLIATTI S, BERTONI F, WALTZER U, FEY MF, BETTICHER DC, SCHEFER H, PICHERT G, STAHEL R, **KETTERER N**, BARGETZI M, CERNY T. Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK). **J Clin Oncol**. 2005;23:705-11
20. ANTONESCU C, BISCHOF DELALOYE A, KOSINSKI M, MONNIN P, SCHAFFLAND AO, **KETTERER N**, GRANNAVEL C, KOVACSOVICS T, VERDUN FR, BUCHEGGER F. Repeated injections of (131)I-rituximab show patient-specific stable biodistribution and tissue kinetics. **Eur J Nucl Med Mol Imaging**. 2005;32:943-51
21. ZIMMERMANN M, LUTHI, F, ZOUHAIR A, **KETTERER N**, KAMEL ME, BISCHOF-DELALOYE A. PET contribution in oncology. **Rev Med Suisse** 2005;1:1335-8, 1335-42.
22. ZAMAN K, **KETTERER N**, VUILLEMOZ D, STUPP R, LEYVRAZ S. New systemic therapies in oncology. **Rev Med Suisse** 2005;1:1361-2, 1361-5.
23. GHIELMINI M, RUFIBACH K, SALLES G, LEONCINI-FRANSCINI L, LEGER-FALANDRY C, COGLIATTI S, FEY MF, MARTINELLI G, STAHEL R, LOHRI A, **KETTERER N**, WERNLI M, CERNY T, SCHMITZ SF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). **Ann Oncol** 2005;16:1675-82
24. GEORGE AC, OZSAHIN M, JANZER R, AGASSIS S, MEULI R, BAUR AS, FROSSARD V, LEYVRAZ S, **KETTERER N**. Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature. **Bull Cancer** 2005;92:E51-6
25. MOREAU P, HULLIN C, GARBAN F, YACOUB-AGHA I, BENBOUBKER L, ATTAL M, MARIT G, FUZIBET JG, DOYEN C, VOILLAT L, BERTHOU C, **KETTERER N**, CASASSUS P, MONCONDUIT M, MICHALLET M, NAJMAN A, SOTTO JJ, BATAILLE R, HAROUSSEAU JL. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. **Blood** 2006;107:397-403
26. GARBAN F, ATTAL M, MICHALLET M, HULIN C, BOURHIS JH, YAKOUB-AGHA I, LAMY T, MARIT G, MALOISEL F, BERTHOU C, DIB M, CAILLOT D, DEPRIJCK B, **KETTERER N**, HAROUSSEAU JL, SOTTO JJ, MOREAU P. Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. **Blood** 2006;107:3474-80
27. PEDRAZZOLI P, LEDERMANN JA, LOTZ JP, LEYVRAZ S, AGLIETTA M, ROSTI G, CHAMPION KM, SECONDINO S, SELLE F, **KETTERER N**, GRIGNANI G, SIENA S, DEMIRER T. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. **Ann Oncol** 2006;17:1479-88
28. BUCHEGGER F, ANTONESCU C, BISCHOF DELALOYE A, HELG C, KOVACSOVICS T,

KOSINSKI M, MACH J-P, **KETTERER N**. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. *Br J Cancer* 2006;94:1770-6

29. ROSSELET A, **KETTERER N**. Myélome multiple. *Rev Med Suisse* 2007;3:695-700
30. WAVRE A, BAUR AS, BETZ M, MÜHLEMATTER D, JOTTERAND M, ZAMAN K, **KETTERER N**. Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma. *Neuro-Oncology*;2007;9:370-2
31. NAY C, LUTHI F, **KETTERER N**, BAUER J, LEYVRAZ S. Overview on cancer in young adults. *Rev Med Suisse* 2007;3:1305-10.
32. **KETTERER N**, BISCHOF DELALOYE A, HELG C, LUTHI F, BUCHEGGER F. Radioimmunotherapy of follicular lymphoma: a step towards cure? *Bull Cancer* 2007;94:799-806
33. BUCHEGGER F, PRESS OW, BISCHOF DELALOYE A, **KETTERER N**. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. *The Oncologist* 2008;13:657-67
34. FROSSARD V, **KETTERER N**, ROSSELET A, MEIER P, CAIROLI A, DUCHOSAL MA, KOVACSOVICS T. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience. *Annals of Hematology* 2009;88:681-5
35. SCHUSTERBAUER C, CAIROLI A, **KETTERER N**. Lymphoma and pregnancy : how to deal with ? *Rev Med Suisse* 2009;5:1104-1109.
36. HAROUSSEAU JL, AVET-LOISEAU H, ATTAL M, CHARBONNEL C, GARBAN F, HULIN C, MICHALLET M, FACON T, GARDERET L, MARIT G, **KETTERER N**, LAMY T, VOILLAT L, GUILHOT F, DOYEN C, MATHIOT C, MOREAU P. Achievement of at least Very Good Partial Response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy. Long-term analysis of the IFM 99-02 and 99-04 trials. *J Clin Oncol* 2009;27:5720-6
37. LUDWIG H, BEKSAC M, BLADÉ J, BOCCADORO M, CAVENAGH J, CAVO M, DIMOPOULOS M, DRACH J, EINSELE H, FACON T, GOLDSCHMIDT H, HAROUSSEAU JL, HESS U, **KETTERER N**, KROPFF M, MENDELEEVA L, MORGAN G, PALUMBO A, PLESNER T, SAN MIGUEL J, SHPILBERG O, SONNEVELD P, ZWEEGMAN S. Current Multiple Myeloma treatment strategies with novel agents – a European perspective. *The Oncologist*. 2010;15:6-25
38. KRISHNAN B, ELSE M, TJONNFJORD GE, CAZIN B, CARNEY D, CARTER J, **KETTERER N**, CATOVSKY D, ETHELL M, MATUTES E, DEARDEN CE. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukemia results in longer survival than after alemtuzumab alone: a multicenter retrospective study. *Br J Haematol*. 2010;149:707-10
39. ADVANI A, PATEL H, COIFFIER B, CZUCZMAN MS, DREYLING M, FORAN J, GINE E, GISSELBRECHT C, **KETTERER N**, NASTA S, ROHATINER A, SCHMIDT-WOLF IGH, SCHULER

M, SIERRA J, SMITH MR, VERHOEF G, WINTER JN, BONI J, VANDENDRIES E, SHAPIRO M, FAYAD L. A Phase 1 Study of Inotuzumab Ozogamicin (CMC-544) as Treatment for B-Cell Non-Hodgkin's Lymphoma. **J Clin Oncol** 2010;28:2085-93

40. TAVERNA C, BARGETZI M, BETTICHER D, GMÜR J, GREGOR M, HEIM D, HESS U, **KETTERER N**, LERCH E, MATTHES T, MEY U, PABST T, RENNER C. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. **Swiss Med Wkly** 2010 Sept 13;140:w13054
41. GISSELBRECHT C, GLASS B, MOUNIER N, GILL DS, LINCH D, TRNENY M, BOSLY A, **KETTERER N**, SHPILBERG O, HAGBERG H, MA D, BRIERE J, MOSKOWITZ CG, SCHMITZ N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era: a CORAL study. **J Clin Oncol** 2010;28:4184-90
42. CICONE F, RUSSO E, CARPANETO A, PRIOR JO, BISCHOF DELALOYE A, SCOPINARO F, **KETTERER N**. Follicular Lymphoma at relapse after rituximab containing regimens: Comparison of time to event intervals prior to and after 90Y-Ibritumomab-Tiuxetan. **Hematol Oncol** 2011;29:131-8
43. MOREAU P, ATTAL M, PEGOURIE B, PLANCHE L, HULIN C, FACON T, STOPPA AM, FUZIBET JG, GROSBOIS B, DOYEN C, **KETTERER N**, SEBBAN C, KOLB B, CHALETEIX C, DIB M, VOILLAT L, FONTAN J, GARDERET L, JAUBERT J, MATHIOT C, ESSELTINE D, AVET-LOISEAU H, HAROUSSEAU JL. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. **Blood** 2011;117:3041-4
44. WANNESON L, LUTHI F, ZUCCA E, ROSSELET A, BAGLIONI M, LERCH E, FEUERLEIN K, GHIELMINI M, **KETTERER N**. Pegfilgrastim Accelerates Neutrophil Engraftment, Reduces the Number of Neutropenic and Hospitalization Days and the Use of Antibiotics After Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma and Lymphoma. A Phase II Study and Comparison with a Filgrastim Treated Historical Cohort. **Leukemia & Lymphoma** 2011;52:436-43
45. LUTHI F, FUCINA N, DIVORNE N, SANTOS-EGGIMANN B, CURRAT-ZWEIFEL C, ROLLIER P, WASSERFALLEN JB, **KETTERER N**, LEYVRAZ S. Home care – A safe and attractive alternative to inpatient administration of intensive chemotherapies. **Support Care Cancer** 2012;20:575-81
46. PROVENCHER S, FERLAY C, ALAOU-SLIMANI K, DEVIDAS A, LEPRETRE S, DE PRIJCK B, SEBBAN C, DE LA FOUCHARDIERE A, CHASSAGNE-CLEMENT C, **KETTERER N**, THYSS A, DELANNOY A, TILLY H, BIRON P, BLAY JY, GHESQUIÈRES H. Clinical **characteristics** and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series. **Hematol Oncol** 2011;29:10-16
47. BUCHEGGER F, ANTONESCU C, HELG C, KOSINSKI M, PRIOR JO, BISCHOF DELALOYE A, PRESS OW, **KETTERER N**. Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission. **J Nucl Med** 2011; 52:896–900

48. HITZ F, **KETTERER N**, LOHRI A, MEY U, PEDERIVA S, RENNER C, TAVERNA C, HARTMANN A, YEOW K, BODIS S, ZUCCA E. Diagnosis and treatment of follicular lymphoma. **Swiss Med Wkly** 2011 Aug 4;141:w13247
49. WAIBEL PACHINGER C, ROSSELET A, BERTHOUSOZ S, LUTHI F, **KETTERER N**. Acute coronary syndrome upon receiving carmustine infusion before autologous stem-cell transplantation. **Hematol Oncol** 2012;30:216-18
50. RENNER C, ZINZANI P, GRESSIN R, KLINGBIEL D, DIETRICH PY, HITZ F, BARGETZI M, MINGRONE W, MARTINELLI G, TROJAN A, BOUABDALLAH K, LOHRI A, GYAN E, BIAGGI C, COGLIATTI S, BERTONI F, GHIELMINI M, BRAUCHLI P, **KETTERER N**. A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. **Haematologica** 2012;97:1085-91
51. SARRO R, FICHE M, BISIG B, **KETTERER N**, BENHATTAR J, ACHTARI C, DE LEVAL L. An unusual uterine tumor with signet ring cell features. **Intern J Gyn Pathol** 2012;31:236-41
52. GARDERET L, IACOBELLI S, MOREAU P, DIB M, CAILLOT D, NIEDERWIESER DW, MASSZI T, FONTAN, MD J, MICHALLET M, GRATWOHL A, MILONE G, DOYEN C, PEGOURIE B, HAJEK R, CASASSUS P, KOLB B, CHALETEIX C, HERTENSTEIN B, ONIDA F, LUDWIG H, VEKEMANS MC, **KETTERER N**, DAGUENEL A, KOENECKE C, GORIN NC, HAROUSSEAU JL, DE WITTE T, MORRIS C, GAHRTON G. Superiority of the Triple Combination "Bortezomib + Thalidomide + Dexamethasone" over the Dual Combination "Thalidomide + Dexamethasone" in Multiple Myeloma Patients Progressing or Relapsing after Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial. **J Clin Oncol** 2012;30:2475-82
53. BUCHEGGER F, PRIOR JO, ALLENBACH G, BAECHLER S, KOSINSKI M, HELG C, CHALANDON Y, RATIB O, BISCHOF DELALOYE A, **KETTERER N**. Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab RIT may correlate with better tolerance. **Clin Nucl Med** 2012;37:960-4
54. WUNDER D, PEREY L; RÉSEAU ROMAND CANCER ET FERTILITÉ, ACHTARI C, AMBROSETTI A, BELLAVIA M, DELALOYE JF, DE ZIEGLER D, GUMY-PAUSE F, HELG C, **KETTERER N**, PETIGNAT P, PRIMI MP, ROSSELET-CHRIST A, ZAMAN K. Fertility preservation in cancer patients. Review of the French speaking part of Switzerland and recommendations for different situations. **Swiss Med Wkly** 2012 Oct 1;142:w13645
55. GISSELBRECHT C, SCHMITZ N, MOUNIER N, SINGH GILL D, LINCH DC, TRNENY M, BOSLY A, MILPIED NJ, RADFORD J, **KETTERER N**, SHPILBERG O, DÜHRSEN U, HAGBERG H, MA DD, VIARDOT A, LOWENTHAL R, BRIÈRE J, SALLES G, MOSKOWITZ CH, GLASS B. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. **J Clin Oncol** 2012;30:4462-9
56. **KETTERER N**, COIFFIER B, THIEBLEMONT C, FERMÉ C, BRIÈRE J, CASASNOVAS O, BOLOGNA S, CHRISTIAN B, CONNEROTTE T, RÉCHER C, BORDESSOULE D, FRUCHART C, DELARUE R, BONNET C, MORSCHHAUSER F, ANGLARET B, SOUSSAIN C, FABIANI B, TILLY

H, HAIOUN C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). **Annals Oncol** 2013;24:1032-7

57. JARDIN F, DELFAU-LARUE MH, MOLINA TJ, COPIE-BERGMAN C, BRIÈRE J, PETRELLA T, CANIONI D, FABIANI B, JAIS JP, FIGEAC M, LEROY K, MARESCHAL S, SALLES GA, COIFFIER B, DELARUE R, PEYRADE F, BOSLY A, ANDRÉ M, **KETTERER N**, HAIOUN C, TILLY H. Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. **Leuk Lymphoma** 2013;54:1898-907
58. BUCHEGGER F, MACH JP, PRESS OW, BISCHOF DELALOYE A, LARSON SM, PRIOR JO, **KETTERER N**. Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies? **Annals Oncol** 2013;24:1948-9
59. CAIROLI A, **KETTERER N**, BARELLI S, DUCHOSAL MA. High-dose therapy and autologous hematopoietic stem cell transplantation in T-cell lymphoma: a single center experience. **Leuk Lymphoma** 2014;55:1827-31
60. MAURER MJ, GHESQUIERES H, JAIS JP, WITZIG TE, HAIOUN C, THOMPSON CA, DELARUE R, MICALLEF IN, PEYRADE F, MACON WR, JO MOLINA T, **KETTERER N**, SYRBU SI, FITOUSSI O, KURTIN PJ, ALLMER C, NICOLAS-VIRELIZIER E, SLAGER SL, HABERMANN TM, LINK BK, SALLES G, TILLY H, CERHAN JR. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. **J Clin Oncol** 2014;32:1066-73
61. SAMARAS P, BARGETZI M, BETTICHER DC, DUCHOSAL MA, HEIM D, HESS U, **KETTERER N**, LERCH E, MATTHES T, MEY U, PABST T, TAVERNA C, ZANDER T, RENNER C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. **Swiss Med Wkly** 2015 Feb 21;145:w14100
62. VAN DEN NESTE E, SCHMITZ N, MOUNIER N, GILL D, LINCH D, TRNENY M, MILPIED N, RADFORD J, **KETTERER N**, SHPILBERG O, DÜHRSEN U, MA D, BRIERE J, THIEBLEMONT C, SALLES G, MOSKOWITZ CH, GLASS B, GISSELBRECHT C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. **Bone Marrow Transplant** 2016;51:51-7
63. COPIE-BERGMAN C, CUILLIÈRE-DARTIGUES P, BAIA M, BRIERE J, DELARUE R, CANIONI D, SALLES G, PARRENS M, BELHADJ K, FABIANI B, RECHER C, PETRELLA T, **KETTERER N**, PEYRADE F, HAIOUN C, NAGEL I, SIEBERT R, JARDIN F, LEROY K, JAIS JP, TILLY H, MOLINA TJ, GAULARD P. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. **Blood** 2015;126:2466-74
64. DUBOIS S, VIAILLY PJ, MARESCHAL S, BOHERS E, BERTRAND P, RUMINY P, MAINGONNAT C, JAIS JP, PEYROUZE P, FIGEAC M, MOLINA TJ, DESMOTS F, FEST T, HAIOUN C, LAMY T, COPIE-BERGMAN C, BRIERE J, PETRELLA T, CANIONI D, FABIANI B, COIFFIER B, DELARUE R, PEYRADE F, BOSLY A, ANDRE M, **KETTERER N**, SALLES G, TILLY H, LEROY K, JARDIN F. Next Generation Sequencing in Diffuse Large B Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. **Clin Cancer Res.** 2016;22:2919-2928

65. COTTING-BODMER S, MOULIN A, HERBORT CP JR, **KETTERER N**, BETZ M, PICA A, SCHALENBOURG A. Can Low Dose Radiation Therapy (2×2 Gy) be Used in Primary Bilateral Conjunctival Follicular Lymphoma? **Klin Monbl Augenheilkd**. 2016;233:524-526. Epub 2016 Apr 26
66. PILORGE S, HAREL S, RIBRAG V, LAROUSSE F, WILLEMS L, FRANCHI P, LEGOFF M, BIAU D, ANRACT P, ROUX C, BLANC-AUTRAN E, DELARUE R, GISSELBRECHT C, **KETTERER N**, RECHER C, BONNET C, PEYRADE F, HAIOUN C, TILLY H, SALLES G, BRICE P, BOUSCARY D, DEAU B, TAMBURINI J. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. **Leuk Lymphoma** 2016;57:2820-2826
67. GHESQUIERES H, LARRABEE BR, HAIOUN C, LINK BK, VERNEY A, SLAGER SL, **KETTERER N**, ANSELL SM, DELARUE R, MAURER MJ, FITOUSSI O, HABERMANN TM, PEYRADE F, DOGAN A, MOLINA TJ, NOVAK AJ, TILLY H, CERHAN JR, SALLES G. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. **Hematol Oncol** 2016 Jun 10. doi: 10.1002/hon.2305. [Epub ahead of print]
68. VOEGELI M, RONDEAU S, BERARDI VILEI S, LERCH E, WANNESON L, PABST T, RENTSCHLER J, BARGETZI M, JOST L, **KETTERER N**, BISCHOF DELALOYE A, GHIELMINI M. Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). **Hematol Oncol**. 2016 Sep 28. doi: 10.1002/hon.2348. [Epub ahead of print]

Other Articles

1. LEYVRAZ S, **KETTERER N**, GROB JP, SCHNEIDER P, VUICHARD P, VON FLIEDNER V, LEJEUNE F: Sequential high-dose chemotherapy with r-metHu-G-CSF (Filgrastim) and infusion of peripheral blood progenitor cells (PBPC) in patients with small cell lung cancer (SCLC). A feasibility study. In: **Cancer treatment, un update**. Ed. by Banzet P, Holland JF, Khayat D, Weil M Springer-Verlag France, Paris, 1994:322-327
2. LEYVRAZ S, **KETTERER N**, PEREY L, BAUER J, VUICHARD P, GROB JP, SCHNEIDER P, VON FLIEDNER V, LEJEUNE F, BACHMANN F: Multiple high-dose combination chemotherapy and G-CSF (filgrastim) as initial treatment for small cell lung cancer (SCLC). In: **Proceedings of the XVIth International Cancer Congress New Dehli 1994** (Eds R.S. Rao, MG Deo and LD Sanghvi), Monduzzi Editore, Bologna, Italy, pp 1215-1218
3. **KETTERER N**, SPATARO V: Chimiothérapie à haute dose et support hématologique avec facteurs de croissance et cellules souches périphériques. **Bulletin suisse du cancer** 1994;3:118-121

4. **KETTERER N, COIFFIER B**: Anticorps anti-CD20: vers une nouvelle arme thérapeutique? **Cancérologie aujourd'hui** 1998; 7: 129-135
5. **KETTERER N**: Traitement de première ligne du myélome : évolutions majeures. Springer Verlag. 2007
6. TAVERNA C, DESALMAND D, GMÜR J, GREGOR M, HESS U, **KETTERER N**, LERCH E, MEY U, PABST T, PASSWEG J, RENNER C, VÖGELI J. Guide pour le traitement du myélome multiple par la lénalidomide chez les patients préalablement traités. **Schweizer Zeitschrift für Onkologie** 3/2010